SCHEMBL4351340

SCHEMBL4351340

CC(C)CCNc1ncnc2ccc(-c3ccc(NC(=O)CCC(=O)O)cc3)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
CYP1A2 P05177 14/20 0.48
ALDH1A1 P00352 13/20 0.48
HSD17B10 Q99714 11/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 1/20 0.48
LMNA P02545 4/20 0.48
CLK4 Q9HAZ1 13/20 0.47
USP2 O75604 8/20 0.47
CYP3A4 P08684 13/20 0.46
TSHR P16473 5/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HIF1A Q16665 4/20 0.46
CYP2D6 P10635 8/20 0.46
CYP2C19 P33261 8/20 0.46
MAPK1 P28482 3/20 0.44
MAP4K4 O95819 1/20 0.44
ALOX15 P16050 1/20 0.42
FYN P06241 1/20 0.42
SRC P12931 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4366746 0.92 CYP1A2 (0.54) L3MBTL1CYP1A2ALDH1A1HSD17B10KDM4E
SCHEMBL4358601 0.90 CYP1A2 (0.47) L3MBTL1CYP1A2ALDH1A1HSD17B10KDM4E
SCHEMBL4355740 0.87 CYP1A2 (0.55) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4358004 0.82 CYP1A2 (0.53) CYP1A2ALDH1A1HSD17B10LMNACLK4
SCHEMBL4362413 0.81 MAP4K4 (0.52) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4355900 0.81 MAP4K4 (0.60) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4358668 0.80 CYP1A2 (0.57) L3MBTL1CYP1A2ALDH1A1HSD17B10KDM4E
SCHEMBL4353661 0.80 CYP1A2 (0.57) L3MBTL1CYP1A2ALDH1A1HSD17B10KDM4E
SCHEMBL4360188 0.79 MAP4K4 (0.48) CYP1A2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4353222 0.79 CYP1A2 (0.56) CYP1A2ALDH1A1HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 L3MBTL1 1143/4885CYP1A2 1131/4885ALDH1A1 2743/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 L3MBTL1 1143/4885CYP1A2 1131/4885ALDH1A1 2743/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 L3MBTL1 2036/4885CYP1A2 1129/4885ALDH1A1 2942/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 L3MBTL1 2604/4885CYP1A2 1078/4885ALDH1A1 3119/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 L3MBTL1 2604/4885CYP1A2 1078/4885ALDH1A1 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.